The Gaithersburg, Maryland-based firm intends to use the proceeds for general corporate purposes, including working capital and product development.
A UK-led international consortium is sequencing tuberculosis genomes and cataloguing drug resistance mutations to enable more rapid NGS-based diagnostics.
The firm will apply its qPCR-enabling technology to detection kits for highly polymorphic regions of HIV that confer resistance to protease inhibitors.
Merck will provide OpGen with access to its library of bacterial pathogens in order to support OpGen's development of rapid DNA tests and a pathogens database.
Called the Antimicrobial Resistance Diagnostic Challenge, the competition is a joint effort between the NIH and the HHS preparedness office.